Search Results 591-600 of 18308 for alopecia
... alopecia \[any grade\], grade \<=2 peripheral neuropathy, or grade \<=2 hypothyroidism stable on hormone replacement) * Have an eastern cooperative oncology ...
The patient must have recovered to baseline or CTCAE ≤ Grade 1 from toxicity due to all prior therapies except alopecia, neuropathy and other non ...
alopecia, neuropathy, and specific laboratory abnormalities). 29. Administration of a live vaccine within 28 days before first dose of study drug. 30 ...
Patients not recovered to Grade 1 or stabilized from the effects (excluding alopecia) of any prior therapy for their malignancies. Concurrent treatment with ...
... alopecia and decreased tendon reflex and to ≤ Grade 1 for all other effects at the time of enrollment, unless otherwise noted. Consult with the Lilly ...
Unresolved toxicity (except alopecia) ≥ Grade 2 National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 [NCI ...
Subject has not fully recovered from the acute toxicities (except alopecia) of any prior anti-cancer therapy. Subject requiring concomitant use of strong ...
Behcet (beh-CHET) disease, also called Behcet syndrome, is a rare condition. It causes blood vessel swelling, called inflammation, throughout the body. Behcet ...
... alopecia and sensory neuropathy grade ≤ 2 is acceptable. Known severe (grade ≥ 3 NCI-CTCAE v5.0) hypersensitivity reactions to monoclonal antibodies, or ...
... alopecia, ototoxicity and neuropathy. Patients must not be receiving any other investigational anti-cancer agents while on study. Patients must not have ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!